메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
손일석 (경희대학교) 임상현 (가톨릭대학교) 김지희 (Department of Internal Medicine Division of Cardiology St. Vincent’s Hospital) 박상민 (Department of Cardiology Nowon Eulji Medical Center) 홍범기 (연세대학교) 이창훈 (중앙보훈병원 내과) 이상현 (양산부산대학교병원 순환기내과) 장대일 (경희대학교) 주성필 (전남대학교) 이상찬 (Department of Neurology Dong-Eui Hospital) 이용호 (연세대학교) Jeon Dong Woon (National Health Insurance Service Ilsan Hospital) 정경태 (을지대학교) Si Jae Rhee (Medical Affairs Department Daiichi Sankyo Korea Co. Ltd.) 조윤진 (Medical Affairs Department Daiichi Sankyo Korea Co. Ltd.) 김종진 (Department of Cardiology CHA Gangnam Medical Center)
저널정보
대한고혈압학회 Clinical Hypertension Clinical Hypertension 제28권 제1호
발행연도
2022.1
수록면
33 - 41 (9page)
DOI
10.1186/s40885-021-00177-z

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
In this prospective, multicenter, non-comparative observational study, the effectiveness and safety of the triple single-pill combination (SPC) of olmesartan/amlodipine/hydrochlorothiazide (OM/AML/HCTZ) were evaluated in a real clinical practice setting in Korean patients with essential hypertension.A total of 3752 patients were enrolled and followed for 12?months after administration of OM/AML/HCTZ. Primary endpoint was change from baseline to month 6 in the mean systolic blood pressure (SBP). Secondary endpoints included changes from baseline in the mean SBP at month 3, 9, 12 and the mean diastolic blood pressure (DBP) at month 3, 6, 9, 12; changes in the mean SBP/DBP according to age and underlying risk factors; and blood pressure control rate (%) at different time points. Adherence to and satisfaction with OM/AML/HCTZ treatment among patients and physicians were assessed by medication possession ratio (MPR) and numeric rating scale, respectively, as exploratory endpoints. Safety was evaluated by the incidence and severity of adverse events (AEs) as well as the discontinuation rate due to AEs. OM/AML/HCTZ administration led to significant reductions in the mean SBP/DBP by 11.5/6.6, 12.3/7.0, 12.3/7.2, and 12.8/7.4?mmHg from baseline to month 3, 6, 9 and 12, respectively ( P <?0.0001). The BP reductions were maintained throughout the 1-year observation period in all patients with different age groups and risk factors (diabetes mellitus, cardiovascular disease, and renal disease). The BP control rate (%) of <?140/90?mmHg was 65.9, 67.9, 68.9, and 70.6% at month 3, 6, 9, and 12, respectively. The mean MPR during the observation period was 0.96. The safety results were consistent with the previously reported safety profile of OM/AML/HCTZ. Treatment with the triple SPC of OM/AML/HCTZ demonstrated significant effectiveness in reducing SBP/DBP and achieving target BP control with high adherence over the 1-year observation period in Korean hypertensive patients and was well-tolerated. CRIS, KCT0002196 , Registered 3 May 2016.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0